| Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study GK Abou-Alfa, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... The Lancet Oncology 21 (6), 796-807, 2020 | 747 | 2020 |
| Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study SJ Lubner, MR Mahoney, JL Kolesar, NK LoConte, GP Kim, HC Pitot, ... Journal of Clinical Oncology 28 (21), 3491, 2010 | 314 | 2010 |
| CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes MG Lubner, N Stabo, SJ Lubner, AM Del Rio, C Song, RB Halberg, ... Abdominal imaging 40, 2331-2337, 2015 | 271 | 2015 |
| Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... JAMA oncology 7 (11), 1669-1677, 2021 | 243 | 2021 |
| Health literacy and health-related quality of life among a population-based sample of cancer patients JL Halverson, AP Martinez-Donate, M Palta, T Leal, S Lubner, MC Walsh, ... Journal of health communication 20 (11), 1320-1329, 2015 | 179 | 2015 |
| Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma PF Peddi, S Lubner, R McWilliams, BR Tan, J Picus, SM Sorscher, ... | 145 | 2012 |
| Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial V Sahai, PJ Catalano, MM Zalupski, SJ Lubner, MR Menge, HS Nimeiri, ... Jama Oncology 4 (12), 1707-1712, 2018 | 115 | 2018 |
| ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase … GK Abou-Alfa, TM Mercade, M Javle, RK Kelley, S Lubner, J Adeva, ... Annals of Oncology 30, v872-v873, 2019 | 109 | 2019 |
| Human paragonimiasis in North America following ingestion of raw crayfish MA Lane, MC Barsanti, CA Santos, M Yeung, SJ Lubner, GJ Weil Clinical Infectious Diseases 49 (6), e55-e61, 2009 | 100 | 2009 |
| A pilot phase II study of valproic acid for treatment of low‐grade neuroendocrine carcinoma TA Mohammed, KD Holen, R Jaskula‐Sztul, D Mulkerin, SJ Lubner, ... The oncologist 16 (6), 835-843, 2011 | 96 | 2011 |
| Precision medicine in colorectal cancer: the molecular profile alters treatment strategies NH Tran, LL Cavalcante, SJ Lubner, DL Mulkerin, NK LoConte, L Clipson, ... Therapeutic advances in medical oncology 7 (5), 252-262, 2015 | 82 | 2015 |
| Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated … AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... Journal of Clinical Oncology 39 (3_suppl), 266-266, 2021 | 59 | 2021 |
| Chronic granulomatous disease presenting with disseminated intracranial aspergillosis A Alsultan, MS Williams, S Lubner, FD Goldman Pediatric blood & cancer 47 (1), 107-110, 2006 | 56 | 2006 |
| A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal … DA Deming, LL Cavalcante, SJ Lubner, DL Mulkerin, NK LoConte, ... Investigational new drugs 34, 168-175, 2016 | 51 | 2016 |
| A multicenter phase 1 study of γ-secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors NK LoConte, ARA Razak, P Ivy, A Tevaarwerk, R Leverence, J Kolesar, ... Investigational new drugs 33, 169-176, 2015 | 46 | 2015 |
| A phase II trial of a histone deacetylase inhibitor panobinostat in patients with low-grade neuroendocrine tumors N Jin, SJ Lubner, DL Mulkerin, S Rajguru, L Carmichael, H Chen, ... The oncologist 21 (7), 785-786g, 2016 | 37 | 2016 |
| Esophagogastric cancers: integrating immunotherapy therapy into current practice MA Patel, JD Kratz, SJ Lubner, NK Loconte, NV Uboha Journal of Clinical Oncology 40 (24), 2751, 2022 | 34 | 2022 |
| Modifying practices in GI oncology in the face of COVID-19: recommendations from expert oncologists on minimizing patient risk E Lou, S Beg, E Bergsland, C Eng, A Khorana, S Kopetz, S Lubner, ... JCO oncology practice 16 (7), 383-388, 2020 | 32 | 2020 |
| Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer MUS Ayvaci, J Shi, O Alagoz, SJ Lubner Medical Decision Making 33 (4), 521-532, 2013 | 30 | 2013 |
| A preclinical and clinical study of lithium in low‐grade neuroendocrine tumors SJ Lubner, M Kunnimalaiyaan, KD Holen, L Ning, M Ndiaye, NK LoConte, ... The oncologist 16 (4), 452-457, 2011 | 30 | 2011 |
